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Dietary free fatty acids (FFAs), such as ω-3 fatty acids, regulate metabolic and anti-
inflammatory processes, with many of these effects attributed to FFAs interacting with a
family of G protein-coupled receptors. Selective synthetic ligands for free fatty acid recep-
tors (FFA1-4) have consequently been developed as potential treatments for type 2 diabetes
(T2D). In particular, clinical studies show that Fasiglifam, an agonist of the long-chain FFA
receptor, FFA1, improved glycemic control and reduced HbA1c levels inT2D patients, with
a reduced risk of hypoglycemia. However, this ligand was removed from clinical trials due
to potential liver toxicity and determining if this is a target or a ligand-specific feature
is now of major importance. Pre-clinical studies also show that FFA4 agonism increases
insulin sensitivity, induces weight loss, and reduces inflammation and the metabolic and
anti-inflammatory effects of short chain fatty acids (SCFAs) are linked with FFA2 and FFA3
activation. In this review, we therefore show that FFA receptor agonism is a potential
clinical target for T2D treatment and discuss ongoing drug development programs within
industry and academia aimed at improving the safety and effectiveness of these potential
treatments.
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INTRODUCTION
In 2013, 382 million people worldwide were characterized as dia-
betic patients with around 90% of patients diagnosed with type
2 diabetes (T2D), a metabolic disorder intrinsically linked with
obesity (1). T2D is defined by insulin resistance in peripheral tis-
sues, such as the liver and muscle, and a loss of pancreatic beta-cell
function, resulting in insufficient insulin secretion (2), and consti-
tutes a risk factor for health issues including cardiovascular disease,
impaired wound healing, blindness, and renal failure (1). Although
T2D can sometimes be controlled through strict diet regulation, a
large number of patients require clinical therapies. Current treat-
ments, such as metformin, sulfonylureas, glucagon-like peptide-1
(GLP-1) receptor agonists, and dipeptidyl peptidase-4 (DPP-4)
inhibitors, are deployed primarily to either improve insulin secre-
tion, peripheral insulin sensitivity, or both (3). However, there
remains a demand for distinct, safe, and effective treatments for
T2D, with the current therapies often associated with side effects
including hypoglycemia and weight gain. Naturally occurring free
fatty acids (FFAs) found in the diet, including ω-3 fatty acids,
have profound effects on metabolic and inflammatory processes
Abbreviations: αLA, α-linolenic acid; DHA, docosahexaenoic acid; CNS, cen-
tral nervous system; DPP-4, dipeptidyl peptidase-4; FFA, free fatty acid; FFA1–4,
free fatty acid receptors 1–4; GIP, glucose-dependent insulinotropic polypeptide;
GLP-1, glucagon-like peptide-1; GPCR, G protein-coupled receptor; GSIS, glucose-
stimulated insulin secretion; HbA1c, hemoglobin A1c; HFD, high-fat diet; LCFA,
long-chain fatty acid; LPS, lipopolysaccharide; MCFA, medium chain fatty acid;
PYY, peptide YY; SCFA, short chain fatty acid; T2D, type 2 diabetes; TNF, tumor
necrosis factor.
associated with T2D, although the molecular basis for these effects
are complex and incompletely understood (4). FFAs are classi-
fied based upon their chain length, such that short chain fatty
acids (SCFAs) have 1–6 carbon atoms; medium chain fatty acids
(MCFAs) contains 7–12 carbon atoms; and long-chain fatty acids
(LCFAs) contain more than 12 carbon atoms (4). Many of the
biological effects of FFAs have now been attributed, at least in
part, to FFAs interacting with a group of G protein-coupled
receptors (GPCRs) designated the FFA receptors. The most well-
characterized FFA receptors are the two LCFA-specific receptors,
FFA1 and FFA4, and the SCFA-specific receptors FFA2 and FFA3.
FFA receptor agonism, particularly of the FFA1 receptor, has sub-
sequently been shown to have beneficial metabolic effects (4).
Consequently, a number of ongoing industrial and academic pro-
grams are focused upon developing potent and selective synthetic
agonists of FFA1. Although currently less developed, activation of
each of FFA2, FFA3, and FFA4 has also been suggested to have
potential benefits for metabolic function. In this review, we will
therefore discuss the potential of FFA receptor agonists as novel
clinical treatments for T2D.
FFA1
FFA1, activated by various saturated (e.g., palmitic acid, C16:0),
mono-unsaturated (e.g., oleic acid, C18:1), and polyunsatu-
rated long-chain FFAs (e.g., linoleic acid, C18:2) (Table 1), is
a Gq/11-coupled GPCR predominantly expressed in pancreatic
beta cells that is associated with increased glucose-stimulated
insulin secretion (GSIS) (4–6) (Figure 1). FFA1 is also expressed
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Table 1 | FFA receptor agonists for the treatment ofT2D.
FFA receptor Agonists Metabolic effects Clinical trial status
FFA1 Natural ligands: palmitic acid,
oleic acid, linoleic acid
Synthetic ligands: GW9508,
TAK-875/Fasiglifam, AMG-837,
AM-1638, AM-5262, LY2881835,
JTT-851, P11187, TUG-469,
TUG-424, TUG-770, AS2575959,
DS-1558
Improved fasting hypoglycemia and
glucose tolerance in diabetic animal
models
Increased GSIS
Increased incretin release (full
agonists: AM-1638, AM-5262,
LY2881835)
No associated hypoglycemia in
normoglycemic rats
TAK-875/Fasiglifam (Takeda): phase I/II trials showed
reduced blood glucose levels, increased insulin levels,
1.2–1.4% reduction in HbA1c levels with no associated
weight gain/hypoglycemia in T2D patients. Removed
from phase III trials due to potential liver toxicity
AMG-837 (Amgen) and LY2881835 (Eli Lilly):
removed from phase I trials due to toxicity
JTT-851 (JapanTobacco): currently in phase II trials
P11187 (Piramal): currently in phase I trials
FFA2 Natural ligands: acetate
(preferred), propionate, butyrate
Synthetic ligands: AMG7703/
4-CMTB, Euroscreen compounds,
compounds 1 and 2
Improved glucose uptake
Decreased colon motility/contractility
Increased GLP-1 secretion
Inhibition of leukocyte activation
No agonists currently in clinical trials
FFA3 Natural ligands: propionate
(preferred), butyrate, acetate
Increased GLP-1 secretion No agonists currently in clinical trials
Synthetic ligands: Arena
Pharmaceuticals series
FFA4 Natural ligands: α-linolenic acid
(αLA), docosahexanoic acid (DHA)
Synthetic ligands: GW9508,
NCG21, NCG46, TUG-891
Protection against diet-induced obesity
Improved insulin sensitivity and
glycemic control
Increased GLP-1 release
Increased insulin secretion (largely
attributed to GLP-1 release)
Reduced inflammation
No compounds currently in clinical trials although a
number of companies have patented FFA4 agonists
for the treatment of T2D (Banyu Pharmaceutical,
Metabolex, Kindex Therapeutics, Pharma Frontier)
Table 1 illustrates the most commonly described natural and synthetic ligands for FFA1-4. The current clinical status of these synthetic agonists for the treatment of
T2D is also described.
by various enteroendocrine cells where it regulates the release
of incretin hormones such as glucagon-like peptide-1 (GLP-1),
an insulinotropic, anorectic peptide that reduces gastric emp-
tying and motility, as well as cholecystokinin (CCK), shown to
regulate pancreatic secretion, inhibit gastric motility, and reduce
energy intake (7–10) (Figure 1). FFA1 is also present within the
central nervous system (CNS) (11, 12) although whether neu-
ronal FFA1 contributes to the regulation of glucose homeosta-
sis remains to be fully determined (Figure 1). FFA1 expression
has also been reported in glucagon-producing alpha cells within
the pancreas, although this remains controversial (13–17). FFA1
expression has also been well characterized in taste buds where
it mediates, in part, taste preference for fatty acids, although
the significance of this, and possible effects of pharmacological
activation or blockade, remains to be fully elucidated (18, 19)
(Figure 1).
FFA1 AND INSULIN SECRETION
Acute FFA-mediated insulin secretion from isolated human and
rodent islets involves amplification of the second phase of GSIS
(5, 6, 15, 20). This is reduced by approximately 50% in FFA1-null
mice, with the remaining effect attributed to intracellular metabo-
lism of FFAs (5, 6, 15, 20). In contrast, transgenic overexpression of
FFA1 under the control of the mouse insulin II promoter prevents
development of hyperglycemia and improves insulin secretion and
glucose tolerance in diabetic mouse models (21). As anticipated
from this, GW9508, a synthetic FFA1 agonist (Table 1) stimu-
lated GSIS in pancreatic MIN6 cells (22). FFA1 gene expression is
also reduced under glucolipotoxic conditions in rats and in islets
from T2D patients while a rare mutation in the human FFA1
gene is associated with attenuated lipid-mediated enhancement
of GSIS (23–25). The effects of FFA1 on pancreatic beta cell via-
bility, however, has been controversial, with pancreatic-specific
FFA1 overexpression associated with disrupted islet morphology
and impaired beta cell function whereas FFA1 disruption is linked
with increased beta cell viability in mice fed on a high-fat diet
(HFD) (26). These observations promoted the concept that, at
least in the longer term, FFA1 antagonism could be beneficial in
the treatment of diabetes. However, most subsequent pre-clinical
studies contradict these findings, indicating that FFA1 agonism
has no detrimental effects on beta cell viability (16, 20, 21), or
even protects beta cells (27–29).
THE FFA1 AGONIST FASIGLIFAM AND INSULIN SECRETION
Although there are currently no FFA1 agonists approved for
clinical use, considerable interest developed around Fasiglifam
Frontiers in Endocrinology | Diabetes August 2014 | Volume 5 | Article 137 | 2
Watterson et al. FFA receptor agonists and diabetes
FIGURE 1 |The biological effects of FFA receptors. Dietary FFAs, such as
ω-3 fatty acids from fish oils and SCFAs derived from the fermentation of
dietary fiber, have profound effects on metabolic and inflammatory processes
associated with obesity and T2D. These effects have, at least in part, been
attributed to the activation of free fatty acid receptors (FFA1–4), leading to a
great deal of interest in the development of synthetic FFA receptor agonists
for the treatment of metabolic disease. Agonism of the long-chain FFA
receptor FFA1, the most fully characterized of these receptors, improves
glucose-stimulated insulin secretion from the pancreas. Additionally, full
agonists of this receptor increase incretin release from the gut, thereby
indirectly increasing pancreatic insulin secretion, as well as improving
systemic insulin sensitivity and promoting satiety. Agonism of another
long-chain FFA receptor, FFA4, is associated with incretin release from the
gut, as well as an anti-inflammatory effect on macrophages that, in turn, may
improve systemic insulin sensitivity. In the pancreas, FFA4 is associated with
reduced cell apoptosis and FFA4 has recently been detected in alpha and
delta cells and regulates glucagon and somatostatin release, respectively.
Both FFA1 and FFA4 have been detected in taste buds although the full
implications of this in relation to obesity remain to be determined. The SCFA
receptors, FFA2/FFA3, have recently been linked with the beneficial metabolic
effects associated probiotics within the gut. Both receptors have been linked
with incretin release from enteroendocrine cells, as well as both systemic
anti- and pro-inflammatory effects. However, due to conflicting results using
receptor-specific knockout models and a limited selection of pharmacological
tools, more work is required to elucidate the physiological effects of FFA2 and
FFA3 agonism.
(designated TAK-875 in pre-clinical studies, Figure 2), an orally
available FFA1 agonist developed by Takeda (30–32) (Table 1).
Completed Phase II clinical trials demonstrated that T2D patients
treated with Fasiglifam had reduced blood glucose levels, increased
insulin levels, and resulted in a 1.2–1.4% reduction in hemoglo-
bin A1c (HbA1c) levels (32–36) (Table 1). Crucially, although
these effects were comparable to current sulfonylurea treat-
ments, Fasiglifam was associated with markedly less side effects,
with no significant increases in body weight and a reduced
concomitant incidence of hypoglycemia (32–36). This is con-
sistent with pre-clinical data demonstrating that Fasiglifam
improved fasting hyperglycemia and glucose tolerance and aug-
mented GSIS in diabetic rat models, with no hypoglycemia
observed in normoglycemic rats (31). No changes in insulin
resistance have been reported in response to Fasiglifam treat-
ment (37, 38) and Fasiglifam had no effect on glucagon secre-
tion in isolated human islets and did not alter glucagon lev-
els in T2D patients (39). Importantly, prolonged Fasiglifam
exposure was also not associated with beta cell dysfunction or
apoptosis (31).
THE EFFECT OF PARTIAL VS. FULL FFA1 AGONISTS ON
INCRETIN RELEASE FROM ENTEROENDOCRINE CELLS
The ability of synthetic FFA1 agonists to induce significant incretin
release was recently shown to depend upon whether the com-
pound was a partial or full agonist (8, 10, 40) (Figure 1). In this
regard, TAK-875/Fasiglifam had no effect on incretin release from
enteroendocrine cells with similar results reported for AMG-837
(Amgen, Table 1; Figure 2) (39). In contrast, Amgen described
AM-1638 and AM-5262 (Table 1; Figure 2) as full FFA1 ago-
nists that directly stimulate insulin secretion and promote incretin
release from enteroendocrine cells (39, 41, 42) (Figure 1). This
incretin-stimulating effect was abolished in FFA1 knockout mice
and the effect of AM-1638 on glucose homeostasis was attenuated
by the GLP-1R antagonist, Ex(9–39)NH2, indicating a particularly
key role for GLP-1 (39). Similarly, LY2881835, a full FFA1 agonist
from Eli Lilly (Table 1), increased GSIS, lowered blood glucose lev-
els, and increased GLP-1 secretion in animal models (43). Amgen
demonstrated that multiple ligand binding pockets exist on FFA1,
comprising of up to two allosteric sites as well as the FFA binding
orthosteric site (40). One allosteric site is targeted by compounds
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FIGURE 2 | Representative free fatty acid receptor agonists. A number of academic and industrial drug programs are aimed at developing FFA receptor
agonists for the treatment of T2D. A representative selection of the current range of synthetic agonists that have so far been developed for these receptors are
shown.
such as AM-837 and TAK-875 while the second allosteric site is a
target for receptor agonists such as AM-1638 that act as full ago-
nists. Consequently, positive co-operativity was shown between
either AMG-837 or AM-1638 in conjunction with natural FFA lig-
ands in cell based assays measuring second-messenger generation,
as well as primary cell based assays, with positive co-operativity
also reported between AMG-837 and AM-1638 during an oral
glucose tolerance test in a diabetic rodent model (40).
FFA1 AGONISTS: ONGOING FFA1 DRUG PROGRAMS AND
FUTURE CHALLENGES
Although no issues were raised regarding safety and tolerability
during Phase I and II trials, Fasiglifam was recently withdrawn
from phase III trials due to potential liver toxicity (43) (Table 1).
Similarly, Amgen and Eli Lilly removed AMG-837 and LY2881835
(Table 1; Figure 2), respectively from Phase I clinical trials due to
concerns over toxicity (43). However, the pre-clinical and clinical
data generated using Fasiglifam provides a strong rationale and
validation for further studies into the potential use of FFA1 ago-
nism as a novel treatment for T2D. Currently, Japan Tobacco are
conducting Phase II clinical trials with their FFA1 agonist candi-
date, JTT-851 and Piramal have begun Phase I clinical trials on
their FFA1 agonist, P11187 (43) (Table 1). Daiichi Sanyko also
recently described 3-aryl-3-ethoxypropanoic acids as orally active
FFA1 agonists that improve insulin secretion and glucose home-
ostasis in rats (44). Additionally, FFA1 agonists developed by Astel-
las are reported to have beneficial effects on glucose homeostasis in
diabetic mouse models (45, 46). Sanofi and Boehringer-Ingelheim
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are also reported to have FFA1 agonist programs under develop-
ment (43). In an academic context, the University of Southern
Denmark have developed 4-(benzylamine)hydrocinnamic acid
FFA1 agonists such as TUG-469 (47, 48) and 4-alkyne hydrocin-
namic acid FFA1 agonists, including TUG-424 and TUG-770
(49–51) (Table 1). Within these programs, several strategies have
been followed to reduce compound lipophilicity (48, 52, 53). Con-
sequently, TUG-770 (Figure 2) has recently been described as a
highly potent FFA1 agonist with favorable physicochemical and
pharmacokinetic properties, improving glucose tolerance in diet-
induced obese mice. This effect did not desensitize, being fully
maintained after 29 days of chronic dosing (49).
FFA4
FFA4, a Gq-coupled GPCR activated by LCFAs, including α-
linolenic acid (α-LA) and docosahexaenoic acid (DHA) (Table 1),
is expressed in enteroendocrine cells, lung, brain, white adipose
tissues, heart, and liver (4). Within adipose tissue, FFA4 gene
expression is upregulated following a HFD and FFA4 activation
in adipocytes is associated with increased adipogenesis and glu-
cose uptake (54–56), suggesting that FFA4 activation may promote
adiposity and obesity (Figure 1). However, mutation of FFA4
(p.R270H variant) is associated with an increased risk of obe-
sity in European populations (although this variant is almost
absent in a Japanese population), and young FFA4 null mice fed
a HFD gained significantly more fat mass than their wild-type
littermates, suggesting that FFA4 protects against diet-induced
obesity (57). FFA4 agonism is also commonly associated with
improved insulin sensitivity, with FFA4 null mice reported to
have increased fasting glucose and impaired responses to insulin
and glucose tolerance testing (56, 57) (Figure 1). A number of
these metabolic effects, such as increased insulin secretion, sati-
ety, and improved glycemic control, have been attributed, at least
in part, to FFA4-dependent incretin release from enteroendocrine
cells, particularly GLP-1 (4, 54, 55, 58) (Figure 1). GLP-1 secre-
tion was demonstrated both in vitro and in vivo using aLA as
an agonist (58). Similarly, TUG-891 (Figure 2), a potent FFA4
agonist (see below), also increased GLP-1 secretion from STC-1
and GLUTag enteroendocrine cells (55). However, a recent study
has questioned the significance of FFA4-mediated GLP-1 release
(59). FFA4 also co-localizes with the orexigenic peptide, ghrelin,
in duodenal cells in vivo, with recent studies showing that FFA4
activation inhibits ghrelin secretion (60, 61). An emerging role for
FFA4 within pancreatic islets has also recently developed, with the
pancreatic islets of diabetic and hyperglycemic individuals shown
to have decreased levels of FFA4 mRNA and knockdown of FFA4
mRNA levels within islets demonstrated to attenuate the protec-
tive effects of the ω-3 fatty acid, eicosapentaenoic acid against
palmitate-induced cell apoptosis (62) (Figure 1). FFA4 expres-
sion has also recently been detected in delta cells and alpha cells
within the pancreas and was consequently linked with the inhibi-
tion of glucose-dependent somatostatin release and the regulation
of glucagon secretion, respectively (63, 64) (Figure 1). Similar to
FFA1, FFA4 is also expressed in taste buds and is linked with the
regulation of taste preference although, again, the significance of
this in relation to obesity and T2D remains to be clarified (65)
(Figure 1).
THE ANTI-INFLAMMATORY EFFECTS OF FFA4
A recent study indicated that, in addition to the previously
described insulin-sensitizing effects associated with GLP-1 release,
improved systemic insulin sensitivity may also be associated with
FFA4-mediated anti-inflammatory effects on macrophages (56)
(Figure 1). In this study, FFA4 expression in macrophages was
elevated in response to obesity and FFA4 activation decreased
pro-inflammatory gene expression in M1 macrophages and
increased expression of M2 anti-inflammatory genes with reduced
macrophage infiltration of adipose tissues also observed in
FFA4 null mice due to decreased chemotaxis (56). These anti-
inflammatory effects are largely associated with FFA4-mediated
recruitment of β-arrestin 2, a scaffold protein typically associ-
ated with receptor desensitization and internalization that is also
implicated in the regulation of distinct signaling pathways (56, 66,
67). In the case of FFA4, β-arrestin 2 interacts with TAB1 that, in
turn, inhibits lipopolysaccharide (LPS)- and tumor necrosis factor
(TNF)-alpha-induced TAK1 stimulation, thereby blocking toll-
like receptor 4 (TLR4) and the TNF-alpha inflammatory pathways
(56, 66, 67). Interestingly, recent studies have also reported FFA4-
mediated anti-inflammatory effects within the brain. In particular,
FFA4 has been associated with the anti-inflammatory effects of
ω-3 and ω-9 fatty acids in the hypothalamus, thereby reducing
diet-induced inflammation and reducing body adiposity (68, 69)
(Figure 1).
SYNTHETIC FFA4 AGONISTS
Initial synthetic FFA4 agonists, including GW9508, NCG21
(Figure 2), and NCG46 (Table 1), showed significant dual ago-
nism at FFA1 (70). However, our groups have recently reported on
TUG-891, a potent and selective FFA4 agonist (55, 71) (Table 1,
Figure 2), although TUG-891 is significantly less selective for
murine FFA4 compared to murine FFA1, potentially limiting its
use in pre-clinical in vivo studies in mice (71). Recent modeling
and mutational efforts have, however, clearly defined how TUG-
891 interacts with FFA4 (72), information that will be invaluable
in developing novel ligands with improved pharmacological prop-
erties for this receptor. To date, no FFA4 agonists have entered
clinical trials although a number of FFA4 agonist programs are
ongoing. For example, Banyu Pharmaceutical Co. Ltd, IRM LLC
USA, Metabolex, Inc., Kindex Therapeutics, and Pharma Fron-
tier Co., Ltd have all patented FFA4 agonists for the treatment
of metabolic and inflammatory disease (66) (Table 1). Similarly,
GSK has recently described a series of diarylsulfonamides as FFA4
agonists (73) and Metabolex has reported that their series of
dihydrobenzofuran-based FFA4 agonists improved glucose home-
ostasis in mice, with moderate glucose-lowering effects in mice
shown with a separate series of FFA4 agonists (66). Additionally,
Kindex Therapeutics described beneficial effects in the treatment
of obesity, inflammation, and metabolic disorders with alpha acids
that were reported to act both as FFA4 agonists and also as partial
PPARγ agonists (66).
METABOLIC REGULATION BY FFA2 AND FFA3
High fiber intake protects against obesity and T2D via SCFA
production, particularly butyrate, acetate, and propionate, from
bacterial fermentation of dietary fiber in the large intestine (74).
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Moreover, modulation of gut microbiota using pre- and probiotics
in both mice and humans regulates body weight, appetite, and glu-
cose homeostasis (74). These SCFA-mediated beneficial effects on
body weight and glucose homeostasis in HFD-fed mice are due,
at least in part, to FFA2/FFA3-dependent mechanisms, includ-
ing for example increased secretion of incretins, such as GLP-1,
glucose-dependent insulinotropic polypeptide (GIP), and peptide
YY (PYY) (74, 75). These receptors are activated by the SCFAs
produced by fiber fermentation in the gut, with the human FFA2
ortholog preferentially activated by shorter SCFAs, such as acetate,
whereas human FFA3 is activated preferentially by the longer
SCFAs, with propionate being the most potent SCFA for both
receptors, at least in human (4, 74–80) (Table 1; Figure 1). How-
ever, the relative potency and preference for various SCFAs appears
to vary significantly across species (81, 82). SCFA-triggered secre-
tion of GLP-1 was almost completely abolished in primary colonic
cultures from FFA2 null mice and reduced, to a lesser extent, in
mice lacking FFA3 (76). FFA2 is expressed in adipose tissue, intes-
tine, islet cells, enteroendocrine cells, and immune cells while FFA3
is highly expressed in the small intestine, colon, and pancreas (4).
FFA2 expression levels are also elevated in the skeletal muscle,
liver, and adipose tissue of HFD-fed rodents, with FFA2 shown
to regulate adipogenesis and adipocyte differentiation and inhibit
lipolysis (83) (Figure 1).
Complete elucidation of the metabolic effects of FFA2 and FFA3
has, however, been complicated by conflicting results using FFA2
and FFA3 null mice. For example, in one study, HFD-fed FFA2 null
mice display lower body fat mass and improved glucose control
compared to wild-type mice, indicating a role for FFA2 antagonists
in the treatment of T2D (84). Contrastingly, FFA2 null mice were
also shown to be obese on a normal diet, with reduced insulin sen-
sitivity and marked insulin resistance whereas adipocyte-specific
overexpression of FFA2 resulted in lower body weight in a HFD
study (85). Similarly, the loss of FFA3 either resulted in weight
loss, obesity, or had no effect in different studies (86–88). Hence,
the development of more potent and selective FFA2 and FFA3
agonists will hopefully facilitate the elucidation of the metabolic
effects of FFA2 and FFA3 and ultimately provide future treatments
for T2D. Several selective compound series are already known,
especially for FFA2 (89) (Table 1). Small carboxylic acids derived
from the natural SCFA ligands have shown appreciable and pre-
dictable selectivity but have low potency (80). Selective allosteric
agonists of FFA2 were reported by Amgen to regulate lipolysis (e.g.,
AMG7703/4-CMTB, Table 1; Figure 2). However, the clinical use
of these drugs was deemed to be limited due to low solubility
and poor pharmacokinetics (90). Orthosteric FFA2 agonists and
antagonists have also now been reported (82, 91) and used to
demonstrate a role for this receptor in improved glucose uptake,
decreased colon motility and contractility, increased GLP-1 secre-
tion, and inhibiting leukocyte activation (81, 82, 89, 92). FFA3
agonists are even less developed although Arena Pharmaceuticals
has reported a series of FFA3-selective compounds (89) (Table 1).
Pharmacological characterization of compounds from this series
demonstrated that individual members have diverse pharmaco-
logical properties, acting as intrinsic agonists and/or allosterically
modulating the potency or efficacy of the response to SCFA pro-
pionate (93). Hence, although recent microbiota studies highlight
quite elegantly the role that gut-derived SCFAs can play in the
regulation of metabolism, there still remains a great demand for
improved FFA2 and FFA3 agonists to fully unravel and define the
consequences of activation of these receptors for metabolic health.
FUTURE PERSPECTIVES
The withdrawal of FFA1 agonists from clinical trials, particu-
larly Fasiglifam, highlights the critical importance of establishing
whether the adverse effects reported during these clinical trials are
due to FFA1 agonism or the chemical structures of the particu-
lar FFA1 agonists. Additionally, as FFA2, FFA3, and FFA4 agonists
further develop and hopefully enter clinical trials, it will be inter-
esting to see if the same issues highlighted during FFA1 trials will
also arise. Future research should also fully address the relative
effects of partial and full FFA1 agonists, particularly in relation
to allosterism in conjunction with natural FFA ligands. Addition-
ally, dual agonists of FFA1 and FFA4 may have enhanced effects
on insulin secretion and insulin sensitivity compared to selective
FFA1 or FFA4 agonists alone. Similarly, co-therapeutic approaches
involving FFA receptor agonists and current T2D therapies should
be examined. For example, the FFA1 agonist,AS2575959 (Table 1),
acts synergistically with a DPP-IV inhibitor to improve glucose
homeostasis (45) and combination therapy with Fasiglifam and
metformin displayed enhanced anti-diabetic effects in a diabetic
rat model (94). Similarly, the FFA1 agonist, DS-1558 (Table 1),
acts synergistically with exendin-4, a GLP-1 receptor agonist, to
improve glucose homeostasis in diabetic mice (95). Clearly, there
are a number of significant challenges ahead in the development
of clinical treatments based on FFA receptor agonism. However,
should these challenges be met, FFA receptor agonism may provide
a novel and effective way to treat T2D.
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